|Systematic (IUPAC) name|
|Trade names||Neupramir, Pramistar, Remen|
|Legal status||Unscheduled (US)|
|Mol. mass||269.383 g/mol|
|(what is this?)|
Pramiracetam is a nootropic drug derived from piracetam, and is more potent (i.e. lower dosage is used). It belongs to the racetam family of nootropics, and goes by the trade name Remen (Parke-Davis), Neupramir (Lusofarmaco) or Pramistar (Firma). Pramiracetam is used off-label for a wide range of applications.
Pramiracetam was developed by Parke-Davis in the late 1970s. The first patents for this drug appeared in 1978 (Belgium) and 1979 (US), concurrent with its first reporting of nootropic characteristics.
Pramiracetam, like other members of the racetam family, is generally well tolerated by humans. In a study where a small sample of human subjects with varying degrees of Alzheimer's disease were treated for 5–8 weeks, symptoms were few and mild. At relatively low dosages, a few participants reported headaches. One participant at the highest end of the dosage spectrum experienced sleepiness, decreased appetite, and dizziness. In another study where a small sample of healthy, male human subjects were treated for 10 days, no adverse events were reported.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|